NSAID-induced reactions: classification, prevalence, impact, and management strategies

Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the leading cause of hypersensitivity drug reactions. The different chemical structures, cyclooxygenase 1 (COX-1) and/or COX-2 inhibitors, are taken at all ages and some can be easily obtained over the counter. Vasoactive inflammatory mediators like histamine and leukotriene metabolites can produce local/systemic effects. Responders can be selective (SR), IgE or T-cell mediated, or cross-intolerant (CI). Inhibition of the COX pathway is the common mechanism in CI, with the skin being the most frequent organ involved, followed by the lung and/or the nose. An important number of cases have skin and respiratory involvement, with systemic manifestations ranging from mild to severe anaphylaxis. Among SR, this is the most frequent entity, often being severe. Recent years have seen an increase in reactions involving the skin, with many cases having urticaria and/or angioedema in the absence of chronic urticaria. Aspirin, the classical drug involved, has now been replaced by other NSAIDs, with ibuprofen being the universal culprit. For CI, no in vivo/in vitro diagnostic methods exist and controlled administration is the only option unless the cases evaluated report repetitive and consistent episodes with different NSAIDs. In SR, skin testing (patch and intradermal) with 24–48 reading can be useful, mainly for delayed T-cell responses. Acetyl salicylic acid (ASA) is the test drug to establish the diagnosis and confirm/exclude CI by controlled administration. Desensitization to ASA has been extensively used in respiratory cases though it can also be applied in those cases where it is required.

Keywords: NSAIDs, hypersensitivity drug reactions, mechanisms, management

Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are recognized to be the most common drugs involved in hypersensitivity drug reactions (HDR). Until recently, antibiotics, particularly betalactams (BLs), were considered the most important inducers, but after confirmation NSAIDs are now at the front.

Interest in updating information about HDR to NSAIDs (HDR-NSAID), a large family of drugs derives from the research done by the RIRAAF (Spanish acronym for the network for the study of adverse drug reactions [ADR]), reflected in several publications. Although for many years HDR-NSAID were considered to affect adults, they also occur in children and adolescents.

Although a connection exists between atopy and HDR-NSAID, this differs from IgE allergic reactions to drugs, like HDR to BLs, more related with the cross-intolerant (CI) category. Since 2010 several groups have worked focusing on the skin, the most frequent organ involved. The European Academy of Allergy and Clinical Immunology (EAACI) provided a new classification that has been
progressively adopted by many groups worldwide, although not by others, probably due to local/national differences in patterns of drug prescription, medical indications and self-intake of these drugs, as well as in some instances the limited number of cases evaluated in clinical practice in some centers. When subjects complaining of HDR-NSAID develop a reaction they do not consider NSAIDs as the cause because the reaction occurs in the context of different coincidental triggers and the physicians are often not familiar with the procedures to follow. It may take a long time to evaluate these cases, even though several episodes occurred in a patient, sometimes eight or more.

It is surprising that some NSAIDs can be obtained over the counter, and are advertised on TV or in other media. In a study published in the lay press, the two most important chemicals found in depurated water were dioxin and ibuprofen metabolites. The price we are paying for this, as it contributes to the increased exposure, is a rise in the reactions to aryl propionic acids, particularly ibuprofen. This situation resembles that occurring with BL antibiotics, where subjects not only become sensitized or resensitized, but also develop clinical manifestations after hidden exposure.

Leaders in the field, although attempting to conciliate the European and American positions, still have disagreements. This may be related with the expertise of each author in their daily practice rather than differences among countries/populations because common drugs involved are ibuprofen and paracetamol, followed by diclofenac and more recently selective COX-2 inhibitors. In a collaborative study with a Chinese group, a high degree of homology existed with the Spanish population not only in the drugs involved but also in clinical entities. Recent years have seen an increasing number of manuscripts concerning children. The adolescent population might be less exposed to NSAIDs as compared to children, although sports people usually require NSAIDs for treating muscle and bone lesions.

### Classification of HDR-NSAID and mechanisms

ENDA classification has been a reference guide for clinicians and investigators working in this field. This classification is new but rather represents an extension of previous ones but better adapted to daily demands and provides a more precise approach for the diagnosis and management of subjects with HDR-NSAID. However, further improvement of the classification is expected to occur in the coming years, with resulting modifications in the classification.

To the five major groups shown in Table 1 with the corresponding acronyms and two additional entities added: organ-specific reactions and skin/systemic reactions included in the SR category. Most of the proposed mechanisms have been inferred from the clinical manifestations accompanied by basic knowledge obtained mainly from the cases with NERD, although the subject is in fact more complex. A list of NSAIDs is provided in Figure 1 and includes a large number of chemically different organic compounds classified according to the chemical structure.

Considering the entities within the CI category (Table 1), the first proposed mechanism was inhibition of PG synthesis and activation of key cells like mast cells, basophils, and eosinophils. This created a shunting with released metabolites of the LOX pathway, PGD2, and histamine, as well as several cytokines and other protein mediators, including tryptase. However, a more complex mechanism emerges if we look at all the by-products released, the enzymes involved, and the receptors through which the mediators signal.

The most distinctive finding in NERD is not shared by the other entities. It consists of chronic inflammation, mostly with the presence of eosinophils, extending beyond the acute episode. Both COX and LOX mediators contribute to the lesions including an up/downregulation of some by-products, although a product of the COX pathway, PGD2, is also released by mast cells. Other abnormalities extend beyond the classical COX and LOX pathways, including the involvement of lipoxin A4. In this context, an interplay between all these cells plus those of the bronchial and nasal epithelia originate a response that goes beyond the classical TH1/TH2 paradigm.

### Classification in Table 1

**NERD.** Although we cannot state exactly since when, this is no longer the most frequent entity among HDR-NSAID. As ASA is not the most common drug involved, the term NERD seems more appropriate. Besides the classical entity reported, there are entities with less severe manifestations that do not follow the natural course. Within ASA-induced asthma several endotypes have been reported that may correspond to different mechanisms or variations of the same mechanism involved in NERD. To complicate this, we have reported in a small series of cases selective respiratory responders that do not fall into this classification.
NECD.\(^5\) In subjects with active CSU symptoms aggravated after intake of strong COX-1 inhibitors. This may affect up to 30% of CSU cases, although these have not been widely confirmed\(^1\)\(^–\)\(^3\),\(^12\),\(^33\) and other types of urticaria/angioedema like physical urticaria may also be aggravated.\(^71\),\(^72\) Whether NECD represents a subtype or it may occur in any case of CSU has not been clarified so far.

The evidence supporting the mechanism in NECD is based on limited data.\(^12\),\(^15\) The basal abnormal state is not present in CSU and the entity itself may change, with a subsequent variation in the response to NSAIDs.\(^73\) Less is known about the response in NIUA where the evidence is missing and studies are needed to unveil differences with NERD and NECD.\(^74\)

NIUA.\(^5\) This entity has been neglected or given less attention till recently, when our group provided evidence supporting that it was the most prevalent of all entities, confirmed by other groups.\(^1\)\(^–\)\(^5\),\(^6\),\(^9\),\(^73\)–\(^76\) Published literature and classical textbooks still do not accept it but it is expected that in the coming years this entity should be taken into account.\(^12\),\(^77\)–\(^79\) Although anaphylaxis was not included in the first ENDA classification, later reviews have now considered it.\(^80\) Claims by some European groups regarding ENDA classification consider it incomplete and have made us to clarify this,\(^5\) as shown in Table 1. Now in NIUA, we include the combined forms of respiratory plus skin involvement accompanied in certain cases with systemic symptoms.\(^5\)

The mechanism proposed for the entities within this group has been directly inferred from that for NERD and assumed to be the same.\(^12\),\(^56\),\(^81\) Although all strong COX-1 inhibitors can induce reactions, clinical observations suggest that there might be differences in the way they interact with the COX enzymes.\(^82\) For example, ASA induces an irreversible inactivation of COX-1 and COX-2 but differences with other NSAIDs may explain why some subjects having a response to ASA tolerate ibuprofen, diclofenac, or piroxicam even at high dose.\(^3\)\(^,\(^12\),\(^52\),\(^83\) Transient competitive inhibition of prostanoid biosynthesis may also contribute to symptoms,\(^83\) and specific drugs like

| Cat | Group | Mechanism | Entities | Drugs involved |
|-----|-------|-----------|----------|----------------|
| CI  | NERD  | Inhibition PG-LEK pathways | Rhinitis, asthma, rhinosinusitis, nasal polyposis | NSAIDs |
| CI  | NECD  | Unknown | CSU aggravated or reactivated by NSAIDs | NSAIDs |
| CI  | NIUA  | Unknown | Urticaria and/or angioedema, anaphylaxis, mixed reactions | NSAIDs |
| SR  | SNIUAA | IgEAb/others | Anaphylaxis, urticaria and/or angioedema, rhinitis, asthma | Arl-propionics |
| SR  | SNIDHR | T cells | CD Photosensitivity CD Isolated mucosal involvement Bullous and/or desquamative exanthema DRESS TEN AGEP FDE NI urticaria Serum sickness like accelerated urticaria Nicolau syndrome | Diclofenac Naproxen; piroxicam Etoricoxib Diclofenac Ibuprofen; phenylbutazone Ibuprofen; paracetamol; celecoxib Ibuprofen; flurbiprofen; piroxicam Ibuprofen; piroxicam Metamizol Diclofenac; ibuprofen Diclofenac |
| SR  | Organ specific | Mechanism T cells/toxicologic/both | Hepatitis Bile duct syndrome Meningitis | Diclofenac Ibuprofen |
| SR  | Skin/system* | Unknown | Vasculitis | Naproxen; ibuprofen |

Note: \(^*\)Skin plus in some instances systemic manifestations.

Abbreviations: AGEP, acute generalized exanthematic pustulosis; CI, cross-intolerant; CSU, chronic spontaneous urticarial; CD, contact dermatitis; DRESS, drug rash with eosinophilia and systemic symptoms; FDE, fixed drug eruption; NERD, NSAID-exacerbated respiratory disease; NIUA, NSAID-induced urticaria angioedema; NSAID, nonsteroidal anti-inflammatory drug; SNIDHR, single NSAID-induced delayed hypersensitivity reaction; SNIUAA, single NSAID-induced urticaria, angioedema or anaphylaxis; SR, selective responders; TEN, toxic epidermal necrolysis.
piroxicam, although considered a strong COX-1 inhibitor, are better tolerated in cases with skin involvement, but our experience questions whether tolerance occurs in NERD. Paracetamol has been shown to suppress PGE₂ biosynthesis contributing to the imbalance leading to excess production of LOX pathway products.\(^{16,84}\)

The two groups of entities below are considered SR and are induced by specific immunologic mechanisms.

**SNIUAA.**\(^ {55}\) This can be indistinguishable from NIUAA and involves mainly the skin, though when respiratory and/or other organs are involved this is anaphylaxis. Several entities can be included ranging from mild urticaria/angioedema to the more severe forms. Isolated angioedema in the absence of other skin manifestations may occur, and this may be produced by another mechanism still unknown.\(^ {56}\) We include single respiratory responders to several drugs that are not chemically related and that have good tolerance to ASA.\(^ {31,85}\)

**SNIDR.**\(^ {55}\) It includes well-differentiated entities such as NIU, delayed angioedema, exanthematic and bullous

---

**Figure 1** Groups and chemical structures of the different NSAIDs. **Notes:** *Tiaramide is considered an NSAID that does not inhibit the COX enzymes. Republished with permission from Blanca-López N, Somoza-Avarez ML, Bellon T, et al. NSAIDs hypersensitivity: questions not resolved. *Curr Opin Allergy Clin Immunol.* 2018;18(4):291–301. https://journals.lww.com/co-allergy/Abstract/2018/08000/NSAIDs_hypersensitivity___questions_not_resolved.4.aspx. The Creative Commons license does not apply to this content. Use of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact permissions@lww.com for further information. **Abbreviation:** NSAID, nonsteroidal anti-inflammatory drug.
All Positive skin testing with some pirazolones like metamizole or propifenazone, or sIgE to ASA although, this entity has only been studied in SNIUA.

This suggests the specificity of T-cell responses to different metabolites and that low amounts of such metabolites might be generated during in vitro cell culture, allowing stimulation of specific T cells. A similar situation may occur with other NSAIDs, including weak and selective COX-2 inhibitors and further research would be needed.

The four subgroups of T-cell-dependent reactions within the IV group of Classical Gel and Coombs classification have been reported with NSAIDs. Some examples for each one are shown below with the addition of a fifth sub-group.

**Type IVa. Contact and photo-CD.** This is considered a Th1 response with effector T-cell involvement and production of interferon gamma (IFN-γ), IL-12, and other cytokines and chemokines.

**Type IVb: MPE** is the classical entity with activated T cells, CD4, and CD8, which home to the skin and form a perivascular infiltrate that can be accompanied by eosinophils and neutrophils. Activated T cells are present with the expression of several activation markers and production of IL-4 and IL-5.

**Type IVc: SJS-TEN.** This is a very severe entity, both in the histopathology and clinical manifestations, with the presence of activated T cells that release perforin and granzyme-B leading to apoptosis and a massive death of keratinocytes and other cells.

An entity with lesions partly resembling TEN is FDE, though this is usually limited to well-localized areas but sometimes, if more extensive, must be differentiated from SJS-TEN. MPE, which in severe lesions is often named toxicodermia, and CD can often be quite aggressive and involve an important degree of cell death. In fact, MPE can be followed by extensive desquamation in the absence of bullae formation.

**Type IVd: AGEP.** T cells as well as neutrophils are attracted to the skin inducing a typical lesion consisting of small confluent pustules without infected fluid. Lesions are generalized, usually mild, and can produce problems in the clinical course.

**Type IVe. NIU.** Although AX, AX-CLAV, and antibiotics are the most common culprits, NSAIDs are also involved. Although, this entity has only been studied in detail recently showing T-cell activation with the presence in peripheral blood-activated T cells (CD4 and CD8) responsible for the lesions. Skin immunohistopathology is in consonance with the pattern observed in peripheral cells.

**DRESS.** This reaction starts with mild exanthema that may generalize to an intense erythema, often accompanied by angioedema, joint involvement, fever, malaise, and liver damage. Neutrophilia and eosinophilia can also be present.
Other clinical entities in which the mechanisms have not been so extensively studied are included in Table 1.\textsuperscript{115–117}

Focusing on the clinical entities included within the CI groups, a number of claims have been raised, especially with NIUAA, indicating that particularly in children and adolescents both cutaneous and respiratory manifestations may occur.\textsuperscript{60,118} These reactions also occur in adults although in a lower percentage.\textsuperscript{3} Further queries can be raised concerning this classification that rather than invalidating it actually contributes to improving the classification, providing more detailed information on the clinical entities outlined above.\textsuperscript{56}

### Prevalence

Although different approaches concerning adverse drug effects have been made,\textsuperscript{119} few data have focused on HDR-NSAID. Published reports on ADR mostly relate to new drugs\textsuperscript{120,121} and include side effects that go beyond the field of HDR. Once drugs are released on to the market and have lost their novelty as a new drug product or category, interest is gradually lost.\textsuperscript{119} Because ADR including NSAIDs occur in the context of complex situations with many offenders, links to side effects are often not convincing\textsuperscript{122} and side effects to HDR-NSAID may be attributed to errors by the physician or other health care givers.\textsuperscript{119} The term prevalence for HDR in general and even for those groups of drugs like antibiotics is difficult to establish.\textsuperscript{56} Nevertheless, despite the limitations we shall use this term here referring to HDR to NSAIDs.

Propionic acid derivatives are available worldwide, particularly ibuprofen, although there exist country/regional differences.\textsuperscript{4,42} In one study, a consecutive series of >4,000 cases with DHR reactions were evaluated in a period of 6 years. The protocol applied for NSAIDs was as described by the EAACI drug expert committee.\textsuperscript{55} The analysis of the different factors/variables of the study was made by Mann–Whitney tests and chi-square analysis. After confirmation by DPT (drug provocation test) the 47.2 were confirmed as hypersensitivity to multiple NSAIDs followed by antibiotics with an 18%, less than the half and in a minor proportion by other drugs like non-BL antibiotics, contrast media, and other drugs.\textsuperscript{1}

Ibuprofen and paracetamol are the most commonly prescribed drugs in children, with some competition with BLs.\textsuperscript{49,58} When HDR are considered in children some studies indicate that antibiotics are the most frequent before making the final evaluation, after which the opposite occurs.\textsuperscript{5,72} From adolescence up to the oldest people the rest of the NSAIDs shown in Table 2 are progressively prescribed, although ASA has diminished its indication in cardiovascular prophylaxis worldwide.\textsuperscript{123,124} In a large multicentric study conducted under the GA\textsuperscript{2}LEN program, >60,000 cases were evaluated in 22 centers from 15 countries, and the aim was to estimate the prevalence of NERD assessing upper and lower respiratory disorders. For this purpose, cases were selected in each country by random from general physician registries and a questionnaire was undertaken. Sampling probability weights were used to standardize prevalence by gender and 5-year groups. The association of NSAIDs as potential agents inducing respiratory symptoms was made by logistic regression analysis. Results showed a mean prevalence of 1.9% with a variation rank from 0.9 to 4.9 in the different centers included.\textsuperscript{67}

In another study, a systematic review identified patients with NERD selected by either challenge or a self-reported history showing a prevalence of 9% (95% confidence interval 6%–12%) in the cases confirmed by oral provocation test and 9.9% (95% confidence interval 9.4%–10.5%) using a self-reported history\textsuperscript{68} concluding that the prevalence was similar by both approaches. This is similar to other estimations with sufficient data provided for respiratory diseases.\textsuperscript{62} For the other entities within the CI group, and also for SR, fewer data are available and we refer the reader to a recent review giving details on this issue.\textsuperscript{56}

### Impact

As NSAIDs contribute to the highest percentage above all drugs inducing HDR-NSAID and they are widely used as stated above, the impact in managing cases with these reactions is paramount. For dealing with this, we divide this section in three parts: clinical entities, further impact, and role of atopy.

### Clinical entities

The classification in Table 1 provides a guide to allocating the different entities shown above. Because these are described elsewhere,\textsuperscript{12,14,49,50,54,55,62} we will focus on just a few points. Time interval is implicit in clinical manifestations,\textsuperscript{14,29} so to use this variable as discriminative for a new classification is not needed.\textsuperscript{118} Within each group several entities can be identified although more will emerge or be segregated from these as more research is done.

NERD. The natural course is well established and in many cases it may have an unfavorable clinical evolution that needs special surveillance, close attention, and great
A detailed history taking a clinical history. and the previous status of the patient must be recorded when observed by the clinician, the time interval after drug intake, although this can be longer. Nevertheless, we still do not know in which type of CSU aggravation of CSU after NSAID intake may occur in up to 30% of cases. In spite of the progress made in recent years concerning understanding the pathophysiology of CSU, a better phenotyping has now been made. Nevertheless, we still do not know in which type of CSU NSAIDs reactivate or worsen the disease. The clinical manifestations consist of a worsening that can often be latent, very attenuated, or absent. A detailed description of the symptoms reported by the patient or observed by the clinician, the time interval after drug intake, and the previous status of the patient must be recorded when taking a clinical history. The description by the patient is very often quite accurate and matches what we usually observe in the DPT, although fortunately less intense and severe because there is a dose–effect relationship.

Subjects can be exposed without knowing the risks taken and often experience mild symptoms that are not imputed to NSAIDs since it is coincidental with physical factors, other drugs or chemicals, foods, and even psychological triggers that can be confounding factors or cofactors. Respiratory symptoms usually appear in the course of the underlying disease with involvement of the upper and lower airways with nasal polyposis in severe cases. Occurrence before the third and fourth decades of life is unusual and the more common natural order of symptom appearance is the upper airways, followed by the lower airways and later by symptoms elicited by NSAIDs. Triggering factors in the absence of NSAID intake include alcohol, and possibly we must consider other histamine-releasing factors that may aggravate or predispose. Initially atopy was not present but nowadays it is a fact that may correspond to a general increase in atopy in western populations, although the connection is hard to define. Nasal symptoms are quite bothersome and in addition obstruction, rhinorrhea, loss of smell, and anosmia may occur. In cases of polyph recurrence corticoids may be needed for control.

**NECD.** Aggravation of CSU after NSAID intake may occur in up to 30% of cases. In spite of the progress made in recent years concerning understanding the pathophysiology of CSU, a better phenotyping has now been made. Nevertheless, we still do not know in which type of CSU NSAIDs reactivate or worsen the disease. If this does not occur, the mechanism acts in the activation pathway at a level common to the different subphenotypes where the pathophysiology is common for all forms, including the autoimmune and not autoimmune, and possibly other forms of urticaria. The clinical manifestations consist of a worsening that can often be latent, very attenuated, or controlled by medication in the previous state. If this is the case, it requires a more aggressive treatment with the use of CS. Despite this, there are cases in children and adults of development of symptoms involving several organs and thus we are dealing with anaphylaxis. Although less known, some reports point out that physical urticaria and

| Entities          | NIUA | NECD | Mix reaction | SNIUA | SNIDHR |
|-------------------|------|------|--------------|-------|--------|
| Category          | Cl   | Cl   | Cl           | SR    | SR     |
| Urticaria         | Yes  | Yes  | Yes          | Yes   | Yes    |
| Angioedema        | Yes/No | Yes/No | Yes/No   | Yes/No | Yes/No |
| Anaphylaxis       | +    | +    | +++          | –     | –      |
| Time interval     | 1–6 hours | Variable | 2–24 hours | ≤1 hour | 6–24 hours* |
| System symptoms   | No   | No   | Yes/No      | Yes/No | No*   |
| ST                | No value | No value | No value | Optional* | Optional* |
| Skin biopsy       | Optional | Optional | Optional | Optional | Yes |
| Nature evolution  | May disappear | Variable | Variable | May disappear | Unknown |
| Corticoids        | Good | Good | Good | Good | Good |

Notes: The interval can be shorter or in rarer instances longer than 24 hours. If systemic symptoms appear, a DRESS must be ruled out. Anaphylaxis is graded as highly probable (+++), less probable (+), absent (–). Abbreviations: CI, cross-intolerant; NECD, NSAID-exacerbated cutaneous disease; NIUA, NSAID-induced urticaria angioedema; NSAID, nonsteroidal anti-inflammatory drug; SNIUA, single NSAID-induced urticarial; SR, selective responders; ST, skin test.
possibly others\textsuperscript{129} may be worsened by NSAID intake. Although evidence is mostly supported by single cases or small series, more information is needed in this respect but it is not surprising that any type of activation of mast cells, which occurs in all types of urticaria, may cause worsening in certain cases after the pharmacologic interaction after intake of these drugs.\textsuperscript{56}

\textit{NIUAA}. This is the most common entity and it can be confusing when we depend on just the clinical description.\textsuperscript{3} However, the patient history provides clues to differentiate it, like the appearance of urticaria with or without angioedema in a well-delineated pattern at any place or all over the body, being most troublesome on the face. The time interval is usually no longer than 2 hours, although episodes may appear up to 6 hours later or longer, and in many instances angioedema can be predominant or be the sole manifestation.\textsuperscript{27} The natural evolution indicates that this is a well-defined entity that does not convert to NERD over a long period of follow-up, as suggested by some.\textsuperscript{130}

\textit{SNIUAA}. Following the general classification, the two entities that follow belong to SR. Clinical manifestations also include urticaria accompanied or not by angioedema, isolated angioedema, or anaphylaxis, as occurs in NIUAA.\textsuperscript{89} However, organ-specific reactions have recently been reported that, although the skin is not involved, we still include in this section because patients have good tolerance to ASA, as far as we know.\textsuperscript{70} If more evidence is supported by different groups in the coming years, the same term can be used with the extra addition of an “A” for anaphylaxis (NIUAAA). The term acute does not fit well because all the cases of NSAID-DHR are acute with no chronic forms, excluding NECD. The time interval in these reactions is usually <1 hour, but not always, as occurs with the immediate IgE reactions to AX and other BL antibiotics.\textsuperscript{32}

\textit{SNIDR}. The entities included in this group are shown in Table 1, and although NSAIDs are not the main drugs eliciting these reactions, particularly the severe ones, some entities like FDE or MPE can be induced. Much literature has been dedicated to this\textsuperscript{121–133} and in this context we recommend several reviews for further reading.\textsuperscript{54–56,78,103,105}

Further phenotyping

It is becoming clearer that within the five major categories, more phenotypes and subphenotypes are now recognized that help understanding the pathologic mechanisms involved. This extends not only to NERD\textsuperscript{56} but to the other entities.\textsuperscript{56,89} Further phenotyping is not only of interest in understanding new mechanisms but also of clinical relevance in order to establish a prognosis once a diagnosis is made and adequate alternatives are given.\textsuperscript{14–16,56}

\textit{NERD}. Within the classical syndrome known as ASA triad there are several endotypes that have been clearly described by several groups. More subphenotypes have been proposed that need external validation by other groups and in other populations.\textsuperscript{31,134} In one study, significant differences were found in total urinary LTE4 and serum total IgE and also in the eosinophil count in the different subgroups.\textsuperscript{135} As shown above, single respiratory responders to one or several NSAIDs with good tolerance to ASA exist and must not be considered in this group; further details will be given below.\textsuperscript{70}

\textit{NECD}. Although not in all instances, subjects with CSU worsen with NSAIDs, though we do not know which cases develop symptoms after NSAID intake.\textsuperscript{56}

\textit{NIUAA}. In the clinical description of this group, several entities have been included that clearly represent well-differentiated forms.\textsuperscript{3} These have been described in detail in a previous section of this review and reported elsewhere.\textsuperscript{14,17,54,55} The combination of both NERD plus NECD has been reported but much more frequent than NERD are those with mixed reactions. We prefer this term to blended reactions, though it is still pending a defined nomenclature that is awaiting further discussion and consensus agreements.\textsuperscript{14,17} Clinical data in children and adolescents point in this direction.\textsuperscript{22,134} In this context, further consensus to set up the clinical criteria is being demanded.\textsuperscript{56}

\textit{SNIUAA}. Within this category, the entities included can be well defined or be unique, with a variation in symptom expression from less to more severe. Thus, urticaria can be the first step in an anaphylaxis episode that after re-exposure within a short time can be more severe, while the opposite can occur; if a long time has elapsed after the first episode symptoms can be minor or even absent. This is well known with the BL model, particularly in those cases with IgE reactions to AX and some cephalosporins,\textsuperscript{9} and it is extensible to everything, including SNIUAAA.\textsuperscript{56,89} It is clear that isolated angioedema can be a reproducible and consistent entity, without further progression in repeated episodes, but there are no clues as to the underlying mechanism in these cases.\textsuperscript{56}

\textit{NIDHR}. This is the group of HDR-NSAID where the phenotypes are best defined and more consistent, induced
by the different drug as well as the specific mechanism within an effector T-cell response. In fact in a new updated revision, we have included an additional Type IVe corresponding to NIU, also known as accelerated allergic reactions and also serum sickness-like disease.\textsuperscript{110}

**Role of atopy**

Atopy as a trait is a complex definition applied to subjects who develop sensitization to inhalant as well as food proteins and glycoproteins by a mechanism mediated by IgE Abs.\textsuperscript{135} There is a big difference in the prevalence of respiratory compared to oral allergen sensitizations, although both are on the increase. To connect both the GI and the respiratory system is not easy because usually when we are positive to an inhalant, like the case of birch pollen, in most instances we develop symptoms after oral exposure also known as secondary sensitization. When primary sensitization occurs by the oral route although IgE Abs are found, very often subjects are tolerant, and this makes sense because the GI system has been adapted to develop immunologic tolerance to proteins that pass through it.\textsuperscript{136,137} Whether HDR-NSAID are linked with atopy or not is not sufficiently clear, although different references support this\textsuperscript{2,3,56} and further stratification in large numbers of cases and with molecular allergens is needed for a better clarification.\textsuperscript{56} Some cumulative evidence of HDR-NSAID points to an increase in allergic reactions to NSAIDs but appropriate studies with long enough time follow-up periods to support this are lacking. Unreported data from our group show an increase but these are not complete as we did not know the denominator for referring and therefore these comparisons lack accuracy.

**Management**

In this section, we include the first step consisting in diagnosis followed by the management of the cases once the diagnosis has been established.

Following the general description shown in the text, after the clinical history has been taken a clear approach of how to proceed must be elucidated.\textsuperscript{2,3,27} For this purpose, two major categories can be envisaged: CI or SR. If the clinical information is reliable and the number of episodes is provided, the classification can be consistent and definitive. Because NSAIDs are drugs taken very frequently and subjects often take them without medical prescription, they come to the allergist with the diagnosis already made and our intervention consists of making a clear report, including the diagnosis and what recommendations to propose.\textsuperscript{3,27}

If clinical manifestations are limited to the respiratory airways, we are dealing in most instances with CI and NERD is the category we are dealing with and can be rhinitis and/or nasal polyposis and/or asthma,\textsuperscript{62} although there are exceptions.\textsuperscript{32} When in addition to respiratory symptoms patients also report cutaneous symptoms (mixed reactions) the approach is different and will be detailed below. The most frequent reactions are those with cutaneous involvement and, in the event a single episode has occurred, the subject can be CI or SR.\textsuperscript{3,56} In our populations as well as in others, the proportion of CI to SR is 3 to 1.\textsuperscript{1,2} However, great differences may exist not only from country to country but also when we consider different age strata. Children are much more common to be CI than SR,\textsuperscript{138} although not all series agree with this.\textsuperscript{21}

NERD. Cases with the symptoms described above are easily diagnosed without need for further confirmation.\textsuperscript{62} The problems arise when first episode appear and this is the first step in the course of the disease. Rhinoscopy provides information on the status of the mucosa with the presence of obstruction and edema, often signs of infection in the mucus and polyps. All these symptoms must be slight and no polyps present at the onset of the disease.\textsuperscript{139} In computed tomography of the sinus, the extension of the lesion can be seen, as well as opacification.\textsuperscript{140} The more recent procedure of magnetic resonance imaging may be needed when intraorbital and other complications are suspected.\textsuperscript{62} In children, the classical NERD has been rarely reported although cases with upper or lower airway symptoms may occur.\textsuperscript{39,40,69}

Today several diagnostic algorithms are provided that are useful for the diagnosis of NERD. As reported by the ENDA group,\textsuperscript{62} the following are indicators of category and groups within which to classify according to Table 1: upper and/or lower immediate symptoms after NSAID intake whether or not reported by the patient but clearly described in a clinical report, involvement of two or more strong COX-1 inhibitors but also one strong inhibitor and a weak one like paracetamol, the occurrence of several episodes, the existence of previous symptoms, the existence of nasal polyposis and of persistent nasal complaints indicative of rhinosinusitis.\textsuperscript{62} Several episodes with all these characteristics are quite indicative and when some are missing or the history is not reliable, further confirmation is needed. Although several algorithms have been provided through the years, the most updated has been published by the ENDA working group.\textsuperscript{62} Figure 2 provides the steps to follow in the case of NERD evaluation.\textsuperscript{62}
NECD. This is not difficult because CSU appears first and can sometimes be with minor symptoms. In these circumstances, avoidance of the drugs leads to improvement although sometimes additional support with corticoids is needed for a quick and better improvement.85

NIUAA. In this group, because there are alternatives, another NSAID can be the choice and there are quite a large number of drugs that are strong COX-1 inhibitors that can be safely administered.89 Skin testing has only been validated for pirazolones, mostly with metamizole, although sensitivity does not surpass 50%.93 In this sense, basophil activation can be an alternative, though also with limited sensitivity, but cases exist of skin-test negative and basophil positive and vice versa. Putting both techniques together, sensitivity does not increase >60%.89 Recommendations for escalating and the doses with different NSAIDs have been published.3

SNIDR. The problems diagnosing T-cell-mediated reactions come mainly when any NSAID induces a reaction in the context of the intake of several drugs, all of them being strong candidates.56 When this occurs, according to the probability and risk/benefit balance, we must start with the drug that, having no alternatives, has the lowest probability of being responsible. The acute phase is quite useful for monitoring the reactions and seeking immunologic markers. The general approach, valid also for NSAIDs, is to monitor the reaction in both the acute phase and the resolution period, taking samples from peripheral blood and skin. Results show a perivascular mononuclear cell infiltrate in the skin with the presence of CD4+ and CD8+ T cells that are activated expressing IL-25+, early and late lymphocyte activation markers, the presence of IL-12 and IFN-γ, and, depending on the severity of the lesions, perforin and FAS-L. These changes are also observed in parallel in peripheral blood together with the expression of markers on T cells that home to the skin like CLA. Further studies and transcriptomic analysis add additional information to the mechanisms involved in these lesions.141–143

General recommendations for intradermal and patch testing are shown in several reviews.144,145 In this respect, although no large series of T-cell-mediated reactions to NSAIDs are available there are several studies with different drugs from these groups that show the concentration
used for intradermal or patch testing. In general, patch testing is reserved for those NSAIDs that are not soluble, and powder solutions in petrolatum at a concentration of 5%–20% w/w are recommended although a maximum concentration value in a negative control needs to be assessed with new drugs where information is not available in the literature. For investigating photo-allergic reactions, the most effective and widely used method is to perform photo-patch testing prepared in petrolatum and applied in duplicate sets to the skin, irradiating one of them with a UV source, as described.

Because in many instances the information provided by the patients is based on retrospective episodes, and also because sometimes we evaluate reactions that can belong to any of the categories shown above, we provide in Table 2 the characteristics of any of the clinical entities described as well as the different groups to which they belong in order to help to clarify this.

Because NSAIDs are drugs taken and prescribed for many conditions at all ages they cannot be withdrawn without providing alternatives. Once a subject has been diagnosed as having HDR-NSAID, next step is the management and consists of providing clear measures to follow, which must be written in an intelligible language for patients and also for the physicians who in the future need to know the precise diagnosis in order to make any decision as to which drug to prescribe. The EAACI has considered it useful to provide a consensus document (drug allergy passport) with the recommendations needed for each case written in a clear way and also given, in addition to the native language, in English, thus enabling the document to be consulted in any country.

One of the major problems in management is when the patients have not been diagnosed, as occurs in all cases of the first episode as well as in many cases that have had several episodes, an allergological workup never has been carried out. In these instances, allergy centers are not available to undertake an appropriate study although in many countries allergy services now have personal facilities to evaluate subjects with drug allergies, including HDR-NSAID. Drug allergy is not a permanent condition; in many instances, it is not for ever and in others it may get worse and subjects may need further evaluation. Another reason is that new drugs from the same group are released on the market, and often assessing tolerance to these may be required, as occurs in the case of weak COX-1 or new COX-2 inhibitors.

With NSAIDs the diagnostic approach not only implies confirming/excluding HDR-NSAID but also providing safe alternatives needed in the cases of CI, as will be detailed below. With SR, once the diagnosis is made, there are easy alternatives unless a very specific drug is particularly useful for the process to be treated. This is the case of SNIUAA to propionic derivatives where our evidence now has shown that subjects can be SR to ibuprofen but have good tolerance to other propionic acid derivatives. For the other drugs, this must also be considered although cases are rather uncommon. This is the case with selected COX-2 inhibitors where differences in chemical structures and clinical data suggest that an SR to one can develop a reaction to the alternatives. In this sense, this can be extended to oxicams, pyrazolones, and others. Drug allergy management, as is many areas of medicine, is becoming a very personalized approach, and that kind of reasoning may be valuable for physicians on specific occasions.

The other group is SNIDHR and as occurs with BLs, in addition to group-specific responders selective reactions also occur, like with oxicams and ary-propionics. If the drug that is provided belongs to the same group but is not the same drug that induced the reaction, and if it was not severe, an approach to assess tolerance can be done. The same measures as for a challenge should apply, although less stringently in order to accommodate the balance of risks/benefits.

For CI, it is now progressively accepted that in a case of a subject with NSAIDs-HDR a search for a safe alternative must be made. To advise in a case of CI, the safety of paracetamol or even a COX-2 inhibitor must not be taken for granted. Nowadays, since the classical division in five major groups with well-defined characteristics, our position is that when we deal with CI and an alternative drug must be given, it is not the same evaluating cases with NERD as those with NIUAA and NIUAA. Studies with a sufficient number of cases for providing evidence-based recommendations are lacking, although there are some publications that although not fulfilling the requirements are to some extent valid for following their recommendations.

As an important number of patients suffer from the underlying disease the management must include both pharmacologic and other support measures to treat the whole process. Strong COX-1 inhibitors should be avoided and safe alternatives must be provided. Regarding weak COX-1 inhibitors, preferentially COX-2 with some COX-1 effects or selective COX-2, the general idea is that they are well tolerated although in the case of paracetamol doses higher than 500 mg can lead in some instances to worsening of respiratory symptoms that may even lead to manifest bronchospasm.
Whether these patients are more resistant to classical asthma treatment with CS and B₂ inhalers must be considered in severe cases as well as inhaled CS, both needed for control.⁶² The value of panleukast and zileuton was initially emphasized by several manuscripts, although they have not yet attained the generalized use of CS and B₂ inhalers.¹⁵⁴–¹⁵⁷ Regarding biologics, promising avenues are now open with initial evidence from case reports, and a recent study has shown improvement.¹⁵⁸–¹⁶⁰

**NECD.** It is assumed in clinical practice that in subjects with CSU, particularly those very active, ASA and other strong COX-1 inhibitors, including piroxicam, may aggravate the clinical course.¹⁶¹,¹⁶² Whether this can be extended to weak COX-1 inhibitors or selective COX-2 is not known and the general practice is to administer this with reasonable safety.¹⁶¹,¹⁶²

**NIUA.** As occurs with other entities all strong COX-1 inhibitors should be avoided in these patients although some cases tolerate ibuprofen in spite of having a reaction with ASA or other NSAID, though in all instances intolerance to ASA must be proven.³¹,¹⁴,²⁷,³⁰ Cases with any of the clinical entities belonging to this group, if they tolerate ASA, are considered double or triple selective.³⁸ In the case of piroxicam it has been estimated that about 20% of cases may develop symptoms, with 80% having good tolerance,³⁸ but later follow-up of these cases has shown that they can develop mild symptoms after intake (data not published). Other drugs of the group of oxicams are shown to be better tolerated.¹⁶³ Regarding paracetamol, although generally it is well tolerated, investigators who have studied large series of patients have shown that up to 19% of cases may have symptoms after intake.¹⁶⁴ Better tolerance is shown with selective COX-2 inhibitors, although a low percentage of cases (about 10%) may develop symptoms.¹⁶⁵ Another alternative drug that has been tested, not available in many countries, is nabumetone that has been shown to be well tolerated.¹⁶⁶ More recently, a new drug, tiaramide, has been shown to be well tolerated in a reduced number of cases in a Japanese study.¹⁶⁷,¹⁶⁸

**SNIUAA.** The choice in this entity is to look for an alternative drug⁸⁰,⁸⁹ but if any of these drugs must be administered a desensitization procedure must be considered, as shown below. It is expected that with the progress made in the understanding of drugs involved in the prostaglandin–leukotriene pathways, any of the NSAIDs now in use may have specific beneficial/detrimental effects that will in the future need to be considered independently.

Because of the relevance of NSAIDs and considering that they are drugs of absolute necessity, if no alternatives are available, desensitization is an option that can be considered in special cases.⁸⁰ Also, dispensation has been used in the management of those cases that within the NERD group have a poor evolution.¹⁵²,¹⁶⁹–¹⁷¹ The rationale is different than that for IgE-mediated reactions but the final outcomes pursued are similar, to induce some type of tachyphylaxis although additional mechanisms have recently been proposed.⁷³

For NSAID, desensitization ASA is given at initial doses of 40.5 mg with increasing doses given over a period of 1–3 days till achieving a final dose of 325 mg. During this period in some cases minor symptoms appear that can be transitory. Then the dose can be maintained from 325 to 650 mg of ASA daily. This treatment is then maintained over a long time during which patients experience decrease in nasal swelling, better breathing by the nose but no change in the presence of asthma. This approach, initially made at the Scrip Clinic by Stevenson et al, has been now generalized to many American centers and also other located all over the world including Europe.¹⁷² Several protocols have been used and, although they have apparent differences, they, nevertheless, follow the same rational strategy with the use of omalizumab in some cases that may help in the success of the procedure. For further details, we recommend the recent review published by the ENDA study group on NERD.⁶² In cases of NECD, desensitization has been less studied and it is not easy to find cases where we can envisage this.¹⁷³ Because the number of patients treated so far is rather low and adverse effects have been reported, we do not know if cases with NECD are more resistant to ASA desensitization. In any case, in any potential scenario where a certain NSAID is needed, the general approaches made for NERD are also valid here.⁶² Finally, concerning desensitization in SNIUAA no cases yet exist and as far as we are aware no information is available in the medical literature, as can be seen by introducing appropriate key words in PubMed or other database sources.

**Concluding remarks**

Increasing worldwide evidence in the last year supported by many groups is showing that NSAIDs are the most important drug involved in HDR. This observation extends to children and the older people although in these ages more evidence is still needed for supporting the observations made in adults and adolescents. Due to the lack of well-validated in vitro and in vivo tests like skin testing for the diagnosis, DPT is the sole approach in most instances to verify tolerance or confirm hypersensitivity. This requires that many centers involved in drug allergy evaluation include in their services special units dedicated to evaluate drug allergy with the required facilities.
and trained personnel for the diagnosis and management of NSAID-HDR. As the use of these drugs including selective COX-2 inhibitors goes on increasing, this approach must be warranted in allergy services.

Abbreviations
Ab, antibodies; ADR, adverse drug reactions; AGEP, acute generalized exanthematic pustulosis; ASA, acetyl salicylic acid; AX, amoxicillin; AX-CLAV, amoxicillin-clavulanic acid; BLs, betalactams; CD, contact dermatitis; CI, cross-intolerance; COX, cyclooxygenase; COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; CS, corticosteroid; CSU, chronic spontaneous urticaria; DRESS, drug rash with eosinophilia and systemic symptoms; DPT, drug provocation test; EAACI, European Academy of Allergy and Clinical Immunology; ENDA, European Network for Drug Allergy; FDE, fixed drug eruption; GI, gastrointestinal; HDR, hypersensitivity drug reactions; HDR-NSAIDs, hypersensitivity drug reactions to NSAIDs; LOX, lipo-oxygenase; MPE, maculopapular exanthema; NECD, NSAIDs-exacerbated cutaneous disease; NERD, NSAIDs exacerbated respiratory disease; NIU, nonimmediate urticaria; NIUA, NSAID-induced urticaria angioedema; NSAIDs, non-steroidal anti-inflammatory drugs; RIRAAF, Spanish National Network for the Study of Adverse Drug Reactions; sIgE, specific IgE; SJS, SJS-TEN, Steven Johnson Syndrome – toxic epidermal necrolysis; SNIDR, single NSAID-induced delayed reactions; SNIUAA, single NSAID-induced urticaria, angioedema, and anaphylaxis; SR, selective responders.

Acknowledgments
This work is supported by fundings as well as grants PI15/00726 and RD16/0006/0024, from the NIH, the Carlos III Health Institute (ISCIII), ARADYL and FEDER to N Blanca-Lopez, V Soriano, E Garcia-Martin, G Canto, and M Blanca.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Doña I, Blanca-López N, Torres MJ, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22(5):363–371.
2. Blanca-López N, Pérez-Alzate D, Canto G, Blanca M. Practical approach to the treatment of NSAID hypersensitivity. Expert Rev Clin Immunol. 2017;13(11):1017–1027.
3. Doña I, Blanca-López N, Cornejo-García JA, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41(1):86–95.
4. Messaad D, Sahla H, Benahmed S, et al. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med. 2004;140(12):1001–1006.
5. Jares EJ, Baena-Cagnani CE, Sánchez-Borges M, et al. Drug-induced anaphylaxis in Latin American countries. J Allergy Clin Immunol Pract. 2015;3(5):780–788.
6. Çelik G, Pichler WJ, Adkinson NF. Drug allergy. In: Adkinson NF, Brocher BS, Busse WW, Holgate ST, Lemanske RF, Simons FER. Middleton’s Allergy Principles & Practice. Vol 2. 7th ed. St. Louis, MO: Mosby Elsevier; 2009; Chapter 68: 1205–1226.
7. Zhou L, Dhospeshwarkar N, Blumenthal KG, et al. Drug allergies documented in electronic health records of a large healthcare system. Allergy. 2016;71(9):1305–1313.
8. Xing Y, Zhang H, Sun S, et al. Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data. Eur J Pediatr. 2018;177(1):145–154.
9. Blanca M. Allergic reactions to amoxicillin. A changing world? Allergy. 1995;50:772–782.
10. Blanca M, Mayorga C, Torres MJ, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy. 2002;32(2):192–197.
11. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2017.
12. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and non-steroidal antiinflammatory drugs. In: Adkinson NF, Brocher BS, Busse WW, Holgate ST, Lemanske RF, Simons FER, editors. Middleton’s Allergy Principles & Practice. Vol 2. 7th ed. St. Louis, MO: Mosby Elsevier; 2009; Chapter 69: 1227–1243.
13. Network for the Study of Adverse Reactions to Drug and Allergens (RIRAAF). ISCiii, Madrid, Spain. Available from: https://chiri.mayo.ac.uma.es/riraafr/. Accessed February 2, 2019.
14. Blanca-López N, Barrionuevo E, Andreu I, Canto MG. Hypersensitivity reactions to nonsteroidal antiinflammatory drugs: from phenotyping to genotyping. Curr Opin Clin Immunol. 2014;14(4):271–277.
15. Ayuso P, Cornejo-García JA, Blanca-López N, Doña I. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy. 2013;43(10):1097–1109.
16. Gómez F, Perkins JR, García-Martín E, Canto G, Cornejo-García JA. Genetic basis of hypersensitivity reactions to nonsteroidal antiinflammatory drugs. Curr Opin Clin Immunol. 2015;15(4):285–293.
17. Plaza-Serón MDC, García-Martín E, Agündez JA, Ayuso P. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. Pharmacogenomics. 2018;19(13):1069–1086.
18. Perkins JR, Barrionuevo E, Ranea JA, Blanca M, Cornejo-García JA. Systems biology approaches to enhance our understanding of drug hypersensitivity reactions. Clin Exp Allergy. 2014;44(12):1461–1472.
19. Pham DL, Jim JH, Park HS. What we know about non-steroidal drug hypersensitivity. Korean J Intern Med. 2016;3:417–432.
20. Kim SH, Sanak M, Park HS. Genetics of hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs. Immuno Clin North Am. 2013;33(2):177–194.
21. Kidon M, Blanca-Lopez N, Gomes E, et al. EAACI/ENDA position paper: diagnosis and management of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29(5):469–480.
22. Blanca-López N, Pérez-Alzate D, Somoza ML, et al. Pattern of responses of hypersensitivity reactions to NSAIDs in adolescents and young adults. Allergy. 2018;73(S105):1757.
23. Guéant JL, Romano A, Cornejo-Garcia JA, et al. HLA-DRA variants of penicillin allergy in genome-wide fine-mapping genotyping. J Allergy Clin Immunol. 2015;135(1):253–259.

24. Rajan JP, Winge NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–681.

25. Babvsek S, Yilmaz I, Celik G, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergol Immunopathol. 2012;40(4):225–230.

26. Hayashi H, Mitsu C, Nakatani E, et al. Omalizumab reduces cyclosporine leukoencephalopathy and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585–1587.

27. Blanca-López N, Torres JM, Doña I, et al. Value of the clinical history in the diagnosis of urticaria/angiokeratoma induced by NSAIDs with cross-intolerance. Clin Exp Allergy. 2013;43(1):85–91.

28. Asero R. Single NSAID hypersensitivity is associated with atopic status. Eur Ann Allergy Clin Immunol. 2015;47(2):48–53.

29. Blanca-López N, Pérez-Alzate D, Andreu I, et al. Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. Allergy. 2016;71(7):1048–1056.

30. Blanca-López N, Bogas G, Doña I, et al. ASA must be given to classify multiple NSAID-hypersensitivity patients as selective or cross-intolerant. Allergy. 2016;71(4):576–578.

31. Pérez-Alzate D, Cornejo-Garcia JA, Pérez-Sánchez N, et al. Immediate reactions to more than 1 NSAID must not be considered cross-hypersensitivity unless tolerance to ASA is verified. J Investig Allergol Clin Immunol. 2017;27(1):32–39.

32. Pérez-Alzate D, Blanca-López N, Doña I, et al. Asthma and rhinitis induced by selective immediate reactions to paracetamol and nonsteroidal anti-inflammatory drugs in aspirin tolerant subjects. Front Pharmacol. 2016;7:215.

33. Blanca-López N, Doña I, Perkins JR, et al. Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: relevance, natural evolution and relationship with atopy. Int Arch Allergy Immunol. 2014;164(2):147–148.

34. Tuttle KL, Schneider TR, Henrikson SE, et al. Aspirin-exacerbated respiratory disease: not always “adult-onset.” J Allergy Clin Immunol Pract. 2016;4(4):756–758.

35. Erttoy Karagol HI, Yilmaz O, Topal E, Ceylan A, Bakirtas A. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents. Int Forum Allergy Rhinol. 2015;5(5):392–398.

36. Cavkaytar O, Arik Yilmaz E, Karaatmaca B, et al. Different phenotypes of non-steroidal anti-inflammatory drug hypersensitivity during childhood. Int Arch Allergy Immunol. 2015;167(3):211–221.

37. Yilmaz O, Erttoy Karagol IH, Bakirtas A, et al. Challenge-proven nonsteroidal anti-inflammatory drug hypersensitivity in children. Allergy. 2013;68(12):1555–1561.

38. Blanca M, Garcia J, Vega JM, et al. Anaphylaxis to penicillins after non-therapeutic exposure: an immunological investigation. Clin Exp Allergy. 1996;26(3):335–340.

39. Demir S, Olgae M, Unal D, et al. Evaluation of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs according to the latest classification. Allergy. 2015;70(1):1461–1467.

40. Caimmi S, Caimmi D, Boussquet PJ, Demoly P. How can we better classify NSAID hypersensitivity reactions? validation from a large database. Int Arch Allergy Immunol. 2012;159(3):306–312.

41. Kidon MI, Liew WK, Chiang WC, et al. Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti-inflammatory drug allergy. Int Arch Allergy Immunol. 2007;144(1):51–56.

42. Cornejo-Garcia JA, Liou LB, Blanca-López N, et al. Genome-wide association study in NSAID-induced acute urticaria/angiokeratoma in Spanish and Han Chinese populations. Pharmacogenomics. 2013;14(15):1857–1869.

43. Alves C, Romeia AM, Abreu C, et al. Non-steroidal anti-inflammatory drug hypersensitivity in children. Allergol Immunopathol. 2017;45(1):40–47.

44. Hassan A, Ponvert C, Karila C, et al. Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases. Eur J Dermatol. 2008;18(5):561–565.

45. Kidon MI, Kang LW, Chin CW, et al. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatr. 2005;117(5):e675–e680.

46. Cavkaytar O, Arik Yilmaz E, Buyuktiryaki B, et al. Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria. Allergy. 2015;70(2):153–160.

47. Calvo Campoverde K, Giner-Muñoz MT, Martinez Valdez L, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs and tolerance to alternative drugs. An Pediatr (Barc). 2016;84:148–153.

48. Ameratunga R, Randall N, Dalziel S, Anderson BJ. Samter’s triad in childhood: a warning for those prescribing NSAIDs. Paediatr Anaesth. 2013;23(8):757–759.

49. Blanca-López N, Cornejo-Garcia JA, Pérez-Alzate D, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in children and adolescents: selective reactions. J Investig Allergol Clin Immunol. 2015;25(6):385–395.

50. Blanca-López N, Cornejo-Garcia JA, Plaza-Serón MC, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs in children and adolescents: cross-intolerance reactions. J Investig Allergol Clin Immunol. 2015;25(4):259–269.

51. Lovell DJ, Dare JA, Francis-Sedlak M, et al. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2018;16(1):41.

52. Predel HG, Giannetti B, Connolly MP, Lewis F, Bhatt A. Efficacy and tolerability of a new ibuprofen 200 mg plaster in patients with acute sports-related traumatic blunt soft tissue injury/contusion. Postgrad Med. 2018;130(1):24–31.

53. Predel HG, Connolly MP, Bhatt A, et al. Efficacy and safety assessment of acute sports-related traumatic soft tissue injuries using a new ibuprofen medicated plaster: results from a randomized controlled clinical trial. Phys Sportsmed. 2017;45(4):418–425.

54. Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011;66(7):818–829.

55. Kowalski ML, Asero R, Babvsek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–1232.

56. Blanca-López N, Somoza-Alvarez ML, Bellon T, et al. NSAIDs hypersensitivity: questions not resolved. Curr Opin Allergy Clin Immunol. 2018;18(4):291–301.

57. Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017;139(3):764–766.

58. Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566–1576.

59. Pérez-Novó CA, Waterbloom J, Claes C, van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189–1196.

60. Steinke JW, Negri J, Liu L, Payne SC, Borish L. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol. 2014;193(1):41–47.
61. Fajmut A, Emeršič T, Dobovšek A, et al. Dynamic model of eicosanoid production with special reference to non-steroidal anti-inflammatory drug-triggered hypersensitivity. *IET Syst Biol*. 2015;9(5):204–215.

62. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. *Allergy*. 2019;74(1):28–39.

63. Liu T, Laidlaw TM, Katz HR, Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. *Proc Natl Acad Sci U S A*. 2013;110(42):16987–16992.

64. Aktas A, Kurt E, Gulbas Z. Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease. *Inflammation*. 2013;36(6):1553–1559.

65. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. *Ann Intern Med*. 1968;68(5):975–983.

66. Bavbek S, Celik G, Demirel YS, Misirligil Z. Risk factors associated with hospitalizations for asthma attacks in turkey. *Allergy Asthma Proc*. 2003;24(6):437–442.

67. Makowska JS, Burney P, Jarvis D, et al. Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GAALEN) survey. *Allergy*. 2016;71(6):1603–1611.

68. Morales DR, Guthrie B, Lipworth B1, et al. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. *Allergy*. 2015;70(7):828–835.

69. Cavkaytar O, Arik Yilmaz E, Karatacamca B, et al. Different phenotypes of non-steroidal anti-inflammatory drug hypersensitivity during childhood. *Int Arch Allergy Immunol*. 2015;167(3):211–221.

70. Pérez-Alzate D, Blanca-López N, Doña I, et al. Asthma and rhinitis induced by selective immediate reactions to paracetamol and non-steroidal anti-inflammatory drugs in aspirin tolerant subjects. *Front Pharmacol*. 2016;7:215.

71. Palikhe S, Palikhe NS, Kim SH, et al. Elevated platelet activation in patients with chronic urticaria: a comparison between aspirin-intolerant and aspirin-tolerant groups. *Ann Allergy Asthma Immunol*. 2014;113(3):276–281.

72. Aun MV, Blanca M, Garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. *J Allergy Clin Immunol Pract*. 2014;2(4):414–420.

73. Mastalerz L, Setkowicz M, Sanak M, Szecezklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. *J Allergy Clin Immunol*. 2004;113(4):771–775.

74. Lee HY, Ye YM, Kim SH, et al. Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease. *Allergy*. 2017;72(4):616–626.

75. Campo P, Ayuso P, Salas M, et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. *Allergy*. 2013;68(8):1001–1007.

76. Zambonino MA, Torres MJ, Muñoz C, et al. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. *Pediatr Allergy Immunol*. 2013;24(2):151–159.

77. Kowalski ML, Stevenson DD. Classification of reactions to non-steroidal anti-inflammatory drugs. *Immunol Allergy Clin North Am*. 2013;33(2):135–145.

78. Ortega Rodríguez NR, Doña Díaz I, Blanca-López N, et al. Hiper sensibilidad a los antiinflamatorios no esteroideos. In: Dávila González JJ, Jáuregui Presa I, Olagüibel Rivera JM, Zubeldia Ortúño JM, editors. *Tratado de Alergología*. 2nd edition. Madrid: Ergon; 2016; Vol 4, Chapter 19: 1551–1570.

79. Giner MT. Alergia a Fármacos. In: Martín Mateos MA, editor. *Tratado de Alergología Pediatrìca*. 2nd ed. Madrid: Ergon; 2011. Chapter 20: 247–263.

80. Blanca-López N, Pérez-Alzate D, Canto G, Blanca M. Practical approach to the treatment of NSAID hypersensitivity. *Expert Rev Clin Immunol*. 2017;13(11):1017–1027.

81. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on aspirin-induced asthma. *Eur Respir J*. 2000;16(3):432–436.

82. Carmona MJ, Blanca M, García A, et al. Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs. *J Allergy Clin Immunol*. 1992;90(6 Pt 1):873–879.

83. Setkowicz M, Mastalerz L, Podolec-Rubis M, et al. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. *J Allergy Clin Immunol*. 2009;123:174–178.

84. Capone ML, Taccorenlli S, Di Francesco L, Sacchetti A, Sciuili MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. *Prostaglandins Other Lipid Mediat*. 2007;82(1–4):85–94.

85. Pérez-Sánchez N, Bogas G, Cornejo-García JA, et al. Multiple nonsteroidal anti-inflammatory drug hypersensitivity without hypersensitivity to aspirin. *J Allergy Clin Immunol Pract*. 2016;4(3):524–525.

86. Matías E, Ruiz A, Moreno E, et al. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metазol. *Allergy*. 2007;62(12):1462–1464.

87. Loh TY, Cohen PR. Ketoprofen-induced photoallergic dermatitis. *Indian J Med Res*. 2016;144(6):803–806.

88. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photoallergic and phototoxic reactions. *Clin Dermatol*. 2016;34(5):571–581.

89. Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. *Curr Opin Allergy Clin Immunol*. 2009;9(4):293–297.

90. Borja JM, Galindo PA, Gomez E, Feo F. Delayed skin reactions to metamizol. *Allergy*. 2003;58(1):84–85.

91. Angadi SS, Karn A. Ibuprofen induced Stevens-Johnson syndrome – toxic epidermal necrolysis in Nepal. *Asia Pac Allergy*. 2016;6(1):70–73.

92. Gulin SJ, Chiriac A. Diclofenac-Induced allergic contact dermatitis: a series of four patients. *Drug Saf Case Rep*. 2016;3(1):15.

93. Gómez E, Blanca-López N, Torres MJ, et al. Immunoglobulin E-mediated immediate reactions to dipyrone: value of basophil activation test in the identification of patients. *Clin Exp Allergy*. 2009;39(8):1217–1224.

94. Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. *J Allergy Clin Immunol*. 2003;111(4):882–888.

95. Ariza A, García-Martín E, Salas M, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. *Sci Rep*. 2016;6:23845.

96. Blanca M, Perez E, Garcia JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. *Ann Allergy*. 1989;62(4):295–298.

97. Harrer A, Lang R, Grims R, et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. *PLoS One*. 2010;5(10):e13707.

98. Levy M, Zylber-Katz E, Büchtemann A, Bianchi L, Klein R. Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. *Liver*. 2002;22(6):507–513.

99. Herdeg C, Hilt F, Büchtemann A, et al. Demonstration by lymphocyte transformation test. *Drug Saf Case Rep*. 2016;3:459.

100. Federmann G, Becker EW, Tautrot H, Penschuck C, Berg PA. Demonstration by lymphocyte transformation test of the allergic genesis in a case of acute hepatitis. *Dtsch Med Wochenschr*. 1988;113(43):1676–1679. German.
101. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1–17.

102. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011;34(10):821–837.

103. Marchand MS, Autret-Leca E, Bourdais E, Jonville-Béra AP. [Photoallergy to piroxicam: what should be contraindicated?]. Therapie. 2013;68(1):57–58. French.

104. Chen CB, Abe R, Pan RY, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res. 2018;2018(3):1–22.

105. Lerch M, Mainetti C, Terzioli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–168.

106. Balta I, Simsek H, Simsek GG. Flurbiprofen-induced generalized bullous fixed drug eruption. Hum Exp Toxicol. 2014;33(1):106–108.

107. Rho YK, Yoo KH, Kim BJ, Kim MN, Song KY. A case of generalized fixed drug eruption due to a piroxicam plaster. Clin Exp Dermatol. 2010;35(2):204–205.

108. Arochenia L, Zafra MP, Fariña MC, del Pozo V, Fernández-Nieto M. Acute generalized exanthematous pustulosis due to ibuprofen. Ann Allergy Asthma Immunol. 2013;110(5):386–387.

109. di Meo N, Stinco G, Patrone P, Trevisini S, Trevisan G. Acute localized exanthematous pustulosis caused by flurbiprofen. Cuts. 2016;9(85):E9–E11.

110. Gómez E, Blanca-Lopez N, Salas M, et al. Induction of accelerated reactions to amoxicillin by T-cell effector mechanisms. Ann Allergy Asthma Immunol. 2013;110(4):267–273.

111. Parra FM, Pérez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate. Ann Allergy Asthma Immunol. 2016;205(6):E5–E8.

112. Kraleti S, Khatri N, Jarrett D. Serum sickness-like reaction after the administration of penicillin. J Clin Pharm Ther. 2016;41(6):626–631.

113. Watanabe T, Abe M, Tada F, et al. Drug-induced liver injury with peripheral blood. J Clin Pharm Ther. 2016;41(6):626–631.

114. Schmutz JL, Barbauda A, Trechot P. [Phenylbutazone and dexamethasone]. Ann Dermatol Venereol. 2010;137:857.

115. Karmacharya P, Mainali NR, Aryal MR, et al. Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease. Case Rep. 2013;2013:bc2013009571.

116. Baxter KA, Pucher PH, Berry DP, et al. The effect of non-steroidal anti-inflammatory drugs on severity of acute pancreatitis and pancreatic necrosis. Ann R Coll Surg Engl. 2018;100(3):199–202.

117. Aynioglu A, Elicora A, Kaya S. Nicolau syndrome due to diclofenac injection. G Ital Dermatol Venereol. 2016;151(4):452–453.

118. Arikoglu T, Aslan G, Yildirim DD, et al. Discrepancies in the diagnosis and classification of non-steroidal anti-inflammatory drugs hypersensitivity reactions in children. Allergolo Int. 2017;66:418–24.

119. Avorn J. The role of Pharmacoepidemiology in the Health-Care System and Academia. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2012. Chapter 6: 73–83.

120. Oosterhuis I, Zweers P, Rümke H, Muller-Hansma A, van Puijenbroek EP. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines. Pharmacoepidemiol Drug Saf. 2018;17(6):697–709.

121. Nguyen KD, Tran TN, Nguyen MT, et al. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Vietnamese spontaneous adverse drug reaction database: a subgroup approach to disproportionality analysis. J Clin Pharm Ther. 2019;44(1):69–77.

122. Kesselheim A. Pharmacoepidemiology and the law. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Hoboken: Wiley-Blackwell; 2012. Chapter 9: 117–134.

123. Cortellini G, Romano A, Santucci A, et al. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity. Allergy. 2017;72(3):498–506.

124. Al-Ahmad M, Rodriguez-Bouza T, Nurkic M. Establishing a safe administration of ASA in cardiovascular patients with nonsteroidal anti-inflammatory drug hypersensitivity with skin and/or respiratory involvement. Int Arch Allergy Immunol. 2018;175(4):237–245.

125. Jenkins C, Costello I, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434.

126. Cardet JC, White AA, Barrett NA, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014;2(2):208–213.

127. Cornejo-Garcia J, Oussallah A, Blanca M, et al. Genetic predictors of drug hypersensitivity. Curr Pharm Des. 2017;22(45):6725–6733.

128. Chirreza-Ojeda I, Robles-Velasco K, Bedoya-Riestro P, et al. Checklist for a complete chronic urticaria medical history: an easy tool. World Allergy Organ J. 2017;10(1):34.

129. Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol. 1975;93(2):133–144.

130. Doña I, Blanca-López N, Torres MJ, et al. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 2014;69(4):438–444.

131. Goeschke B, Braathen LR. Acute generalized exanthematous pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology. 2004;209(1):53–56.

132. Hanafusa T, Azukizawa H, Matsumura S, et al. Non-pigmenting fixed drug eruption caused by an over-the-counter non-steroidal anti-inflammatory drug: drug-specific CDB+ T lymphocytes identified in peripheral blood. Eur J Dermatol. 2012;22(5):680–682.

133. Roujeau J-C, Albergrenz E, Moritz S, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Immunol. 1985;78(1):22–24.

134. Stevens WW, Schleimer RP. Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis. Immunol Allergy Clin North Am. 2016;36(4):669–680.

135. Lee HY, Ye YM, Kim SH, et al. Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease. Allergy. 2017;72(4):616–626.

136. Pali-Schöll I, Untersmayr E, Klems M, Jensen-Jarolim E, et al. The effect of diet and digestibility on antigenicity of food. Nutrients. 2018;10(9):1129.

137. Fisher HR, du Toit G, Bahnson HT, et al. The challenges of preventing food allergy: lessons learned from leap and eat. Ann Allergy Asthma Immunol. 2018;121:313–319.

138. Blanca-López N, Haroun-Diaz E, Ruano FJ, et al. Acetyl salicylic acid challenge in children with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs differentiates between cross-intolerant and selective responders. J Allergy Clin Immunol Pract. 2018;6(4):1226–1235.

139. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyposis 2012. A summary for otorhinolaryngologists. Rhin. 2012;50(1):1–12.

140. Babvsek S, Yilmaz I, Çelik G, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergol Immunopathol. 2012;40(4):225–230.

141. Posadas SJ, Leiva L, Torres MJ, et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol. 2000;106(4):769–776.
142. Blanca M, Posadas S, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. *Allergy*. 2000;55(11):998–1004.

143. Bellón T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. *Br J Dermatol*. 2010;162(5):1014–1022.

144. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. *Allergy*. 2004;59(11):1153–1160.

145. Dalmau J, Serra-Baldrich E, Roé E, Peramiquel L, Alomar A. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to mepolizumab. *Allergy*. 2007;62(12):1462–1464.

146. Macías E, Ruiz A, Moreno E, et al. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to mepolizumab. *Allergy*. 2007;62(12):1462–1464.

147. Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. *Allergy*. 2011;66(11):1428–1433.

148. Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. *Immunol Allergy Clin North Am*. 2014;34(3):507–524.

149. Kowalski ML, Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity: safety of cyclooxygenase-2 inhibitors. *Treat Respir Med*. 2006;5(6):399–406.

150. Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemokines in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. *Chest*. 2002;121(1):143–150.

151. Dahlen SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(1):9–14.

152. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. *Am J Respir Crit Care Med*. 1998;157(4 Pt 1):1187–1194.

153. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

154. Porcaro F, di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. *Pediatr Pulmonol*. 2017;52(5):E26–E28.

155. Gevaert P, van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. *J Allergy Clin Immunol*. 2011;128(5):989–995.

156. Bachert C, Mannent L, Nacloer RM, et al. Effect of subcutaneous dupilumab on nasal polyph burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. *JAMA*. 2016;315(5):469–479.

157. El Miedany Y, Youssef S, Ahmed I, et al. Safety of etoricoxib, a specific cyclo-oxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. *Ann Allergy Asthma Immunol*. 2006;97(1):105–109.

158. Porcaro F, di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. *Pediatr Pulmonol*. 2017;52(5):E26–E28.

159. Gevaert P, van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. *J Allergy Clin Immunol*. 2011;128(5):989–995.

160. Bachert C, Mannent L, Nacloer RM, et al. Effect of subcutaneous dupilumab on nasal polyph burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. *JAMA*. 2016;315(5):469–479.

161. El Miedany Y, Youssef S, Ahmed I, et al. Safety of etoricoxib, a specific cyclo-oxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. *Ann Allergy Asthma Immunol*. 2006;97(1):105–109.

162. Koschel D, Weber CN, Höflken G. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease. *J Invest Allergol Clin Immunol*. 2013;23(4):275–280.

163. Blanca M, Posadas S, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. *Allergy*. 2000;55(11):998–1004.

164. Bellón T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. *Br J Dermatol*. 2010;162(5):1014–1022.

165. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. *Allergy*. 2004;59(11):1153–1160.

166. Dalmau J, Serra-Baldrich E, Roé E, Peramiquel L, Alomar A. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to mepolizumab. *Allergy*. 2007;62(12):1462–1464.

167. Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. *Allergy*. 2011;66(11):1428–1433.

168. Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. *Immunol Allergy Clin North Am*. 2014;34(3):507–524.

169. Kowalski ML, Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity: safety of cyclooxygenase-2 inhibitors. *Treat Respir Med*. 2006;5(6):399–406.

170. Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemokines in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. *Chest*. 2002;121(1):143–150.

171. Dahlen SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165(1):9–14.

172. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. *Am J Respir Crit Care Med*. 1998;157(4 Pt 1):1187–1194.

173. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(3):459–460.

174. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

175. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

176. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

177. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

178. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

179. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

180. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

181. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.

182. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol Pract*. 2015;3(5):711–718.